Prelude Therapeutics Inc (PRLD NASDAQ) stock market data APIs
$3.7526
0.14(3.7%)
as of October 12, 2026
Try our APIs with
free plan!
Prelude Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prev. Close
3.7526
Open
3.8972
High
3.9043
Low
3.7083
52 wk Range
1.16-6.83
Market Cap
310 M
Shares Outstanding
64 917 K
Revenue
22 424 K
EPS
-0.14
Beta
0.962
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Prelude Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Prelude Therapeutics Inc data using free add-ons & libraries
Get Prelude Therapeutics Inc Fundamental Data
Prelude Therapeutics Inc Fundamental data includes:
- Net Revenue: 22 424 K
- EBITDA: -64 510 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Prelude Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-11
- EPS/Forecast: -0.17
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Prelude Therapeutics Inc News
New
Biotech Breakout: What's in focus after Moderna's cancer win?
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalph...
Prelude Narrows Loss In Q2 On Lower Costs; Expects Initiation Of PRT13722 Phase 1 In Q4 FY26
(RTTNews) - Prelude Therapeutics Incorporated (PRLD), a clinical-stage precision-oncology company, reported second quarter results, showing a narrower loss primarily driven by increased revenue and re...
Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?
(RTTNews) - Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Ki...
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeut...
Get Prelude Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.